Policy, venture capital powering commercial rollouts
Inside a quiet rehabilitation ward in eastern China, a paralyzed patient stares intently at a plastic cup. He doesn't move a muscle, yet a robotic, pneumatic glove encasing his paralyzed hand suddenly hums to life, smoothly closing its fingers around the cup.
The invisible trigger? His sheer intention.
By decoding neural signals and bypassing severed spinal cords entirely, brain-computer interface (BCI) technology is performing what looks like medical magic. But behind this clinical breakthrough lies a rapidly maturing business ecosystem. Driven by a strategic influx of venture capital and robust policy tailwinds, BCI is fast graduating from academic curiosity to early commercial deployment.
For years, the BCI sector was a pure-play scientific endeavor confined to university labs. Today, it is arguably the hottest frontier in venture capital.
Data from a recent report by the Beijing-based Fourth Wave Technology Think Tank and Zhongguancun Tiancheng Innovation Research Center paint a staggering picture. Throughout 2025, Chinese BCI startups recorded at least 24 financing events, raising more than 1.45 billion yuan ($212.1 million). In stark contrast, the first three months of 2026 alone saw at least 17 funding rounds, with the total capital raised already eclipsing the entirety of 2025.
The report projects China's BCI market could breach the 5-billion-yuan mark in 2026, on track to reach 15 billion yuan by 2030.
The deal flow reflects this bullish sentiment. Hangzhou-based Brain-Co closed a massive 2-billion-yuan funding round in January. More recently, Shanghai-based medical neurotech firm StairMed secured 500 million yuan, bringing its total funding to more than 1.1 billion yuan within a single year.
"The technology is at an inflection point, transitioning from experimental verification to early clinical implementation," Gu Xiaosong, an academician of the Chinese Academy of Engineering, said at a BCI developer conference in Tianjin. He attributes this shift to breakthroughs in artificial intelligence, machine learning algorithms, and high-performance computing, which are finally transforming laboratory prototypes into clinical-grade medical systems.
In July 2025, China issued BCI industry development guidelines, urging breakthroughs in core hardware/software, high-performance products and real-world applications. Beijing, Shanghai, Shandong province and others introduced supportive policies.
In the 2026 Government Work Report, BCI was formally designated as a future industry, prioritized alongside strategic sectors such as advanced robotics and embodied AI. This alignment underscores BCI's role not only as a medical tool, but also as a critical control component for the next generation of intelligent machines.
The true catalyst for the current market exuberance was a recent regulatory breakthrough. China's National Medical Products Administration approved the world's first implantable BCI medical device for clinical use.
Dubbed the NEO system, the semi-invasive device acts as a wireless translator between the brain and the body, specifically designed to help patients with cervical spinal cord injuries regain hand-grasping functions.
Developed by a Tsinghua University research team led by professor Hong Bo from the School of Biomedical Engineering in collaboration with Neuracle, the NEO system represents a different technological approach from some Western competitors.
In the United States, Elon Musk's Neuralink is pursuing a fully invasive route, implanting electrodes directly into brain tissue. While this can yield high-resolution signals, it involves more invasive surgery and associated risks.
Tsinghua's NEO, by contrast, is implanted with its main device embedded in the skull, while electrodes are placed over the dura mater between the skull and the cerebral cortex, without penetrating brain tissue.
"For quadriplegic patients with cervical spinal injuries who can't grasp objects, we implant a coin-sized device outside the dura mater using minimal invasive surgery,"Wang Yujing, Neuracle product director, told People's Daily.
"The system decodes brain signals in real time, enabling them to control a pneumatic glove with their thoughts to grasp objects or drink water," she added.
The clinical data are highly promising. In trials conducted across 11 Chinese hospitals, all participants achieved brain-controlled grasping. The system boasted a decoding accuracy exceeding 90 percent, with a response delay of mere milliseconds. Furthermore, the implant is powered wirelessly through near-field communication, eliminating the need for internal batteries and risky replacement surgeries.
Despite the hype surrounding surgical implants, the reality of today's commercial landscape is far less invasive.
According to the China Academy of Information and Communications Technology, noninvasive systems — such as wearable EEG headsets — currently account for more than 80 percent of China's BCI market. Because they require no surgery, companies are already monetizing these devices, rolling out products ranging from neuro-feedback headbands for gamers and students, to advanced sleep-monitoring systems.
Yet, beneath the soaring valuations, sobering technical and ethical hurdles remain.
For implantable devices, the human body's immune system is a formidable opponent. Over time, the body forms scar tissue around implanted electrodes, which can degrade signal quality.
Data scarcity is another major bottleneck. Unlike generative AI models that are trained on billions of readily available internet texts, BCI algorithms require highly sensitive neural data, which is exceedingly difficult and expensive to collect.
Then there is the issue of cognitive privacy. Recognizing the profound ethical implications of "reading minds", China's Ministry of Science and Technology issued the country's first national ethical guidelines for BCI research in February 2024, ensuring the technology remains "tech for good" and prioritizing patient autonomy.
"The approval of the first product is just the beginning," noted Hong of Tsinghua University. Scientists are still grappling with deep biological mysteries, such as how these interfaces interact with the brain's natural plasticity, and whether they can actually help heal the nervous system rather than just act as a high-tech crutch.
For now, medical rehabilitation will be the industry's most viable cash cow. But the ultimate ceiling of the BCI market remains unknown.
Translating the silent symphony of human thought into code remains one of the most complex engineering challenges in modern history. As one researcher put it: decoding any conventional computer system is child's play compared to understanding the human brain.




























